0000899243-18-008659.txt : 20180327 0000899243-18-008659.hdr.sgml : 20180327 20180327182527 ACCESSION NUMBER: 0000899243-18-008659 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180327 FILED AS OF DATE: 20180327 DATE AS OF CHANGE: 20180327 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Novartis Institutes for BioMedical Research, Inc. CENTRAL INDEX KEY: 0001673852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38433 FILM NUMBER: 18716650 BUSINESS ADDRESS: STREET 1: 250 MASSACHUSETTS AVENUE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: (617) 871-8000 MAIL ADDRESS: STREET 1: 250 MASSACHUSETTS AVENUE CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NOVARTIS AG CENTRAL INDEX KEY: 0001114448 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38433 FILM NUMBER: 18716649 BUSINESS ADDRESS: STREET 1: LICHTSTRASSE 35 CITY: BASEL STATE: V8 ZIP: CH 4056 BUSINESS PHONE: 01141613241111 MAIL ADDRESS: STREET 1: LICHTSTRASSE 35 CITY: BASEL STATE: V8 ZIP: CH 4056 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Homology Medicines, Inc. CENTRAL INDEX KEY: 0001661998 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473468154 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 WIGGINS AVE. CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 857-305-1825 MAIL ADDRESS: STREET 1: 45 WIGGINS AVE. CITY: BEDFORD STATE: MA ZIP: 01730 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2018-03-27 0 0001661998 Homology Medicines, Inc. FIXX 0001673852 Novartis Institutes for BioMedical Research, Inc. 250 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 0 0 1 0 0001114448 NOVARTIS AG LICHTSTRASSE 35 BASEL V8 CH 4056 SWITZERLAND 0 0 1 0 Series B Preferred Stock Common Stock 1979226 D The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. The securities reported herein are held of record by Novartis Institutes for BioMedical Research, Inc. ("NIBRI"). NIBRI is an indirect wholly-owned subsidiary of Novartis AG. Novartis AG may therefore be deemed to have or share beneficial ownership of the Series B Preferred Stock held directly by NIBRI. Novartis Institutes for BioMedical Research, Inc., By: /s/ Scott A. Brown, VP, General Counsel 2018-03-27 Novartis AG, By: /s/ Stefan Thommen, Authorized Signatory, By: /s/ Susan Jones, Authorized Signatory 2018-03-27